Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767348 | 1.00 | KCNH2 (0.68) | KCNH2SLC2A1 | |
| SCHEMBL2767059 | 1.00 | KCNH2 (0.68) | KCNH2SLC2A1 | |
| SCHEMBL13244842 | 0.93 | KCNH2 (0.65) | KCNH2SLC2A1 | |
| SCHEMBL13244966 | 0.91 | KCNH2 (0.56) | KCNH2 | |
| SCHEMBL2767109 | 0.90 | KCNH2 (0.83) | KCNH2 | |
| SCHEMBL5136329 | 0.90 | KCNH2 (0.83) | KCNH2 | |
| SCHEMBL2767486 | 0.90 | KCNH2 (0.83) | KCNH2 | |
| SCHEMBL13244717 | 0.90 | KCNH2 (0.55) | KCNH2SLC2A1 | |
| Hydrochloric Acid SCHEMBL2769151 | 0.89 | KCNH2 (0.82) | KCNH2SLC2A1 | |
| SCHEMBL2768460 | 0.89 | KCNH2 (0.54) | KCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | BALLELL-PAGES LLUIS | 2010-07-22 | — | — | US | disclosed |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | BALLELL-PAGES LLUIS | 2010-07-22 | — | — | US | disclosed |
| US-7732460-B2 | Heterocyclic compounds, their preparation and their use as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-7732460-B2 | Heterocyclic compounds, their preparation and their use as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| EP-2167196-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| WO-2009000745-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000745-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185153-A1 | COMPOUNDS | NRDC, NISCH, MRPL21 | KCNH2 3013/4885SLC2A1 3396/4885 |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | SDHA, SDHB, NNT | KCNH2 2498/4885SLC2A1 4038/4885 |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | MRPL21, NACA, NISCH | KCNH2 1599/4885SLC2A1 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.